Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from C4 Therapeutics ( (CCCC) ).
On September 20, 2025, C4 Therapeutics announced data from its Phase 1 clinical trial of cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma. The trial showed promising results with a 50% overall response rate at the highest dose level and a differentiated safety profile, supporting further development for potential accelerated approval. The company plans to initiate Phase 2 and Phase 1b studies in 2026, aiming to position cemsidomide as a class-leading treatment option.
The most recent analyst rating on (CCCC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
C4 Therapeutics’ overall stock score is primarily influenced by its strong technical performance, indicating bullish momentum. However, significant financial challenges and a poor valuation due to ongoing losses weigh heavily on the score. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science. The company is dedicated to developing therapies for relapsed/refractory multiple myeloma, with a market focus on IKZF1/3 degraders.
Average Trading Volume: 1,613,636
Technical Sentiment Signal: Hold
Current Market Cap: $224.9M
For a thorough assessment of CCCC stock, go to TipRanks’ Stock Analysis page.